JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M407005200 on January 4, 2005

J. Biol. Chem., Vol. 280, Issue 10, 8951-8960, March 11, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/10/8951    most recent
M407005200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garzón, J.
Right arrow Articles by Sánchez-Blázquez, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garzón, J.
Right arrow Articles by Sánchez-Blázquez, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Activation of µ-Opioid Receptors Transfers Control of G{alpha} Subunits to the Regulator of G-protein Signaling RGS9-2

ROLE IN RECEPTOR DESENSITIZATION*

Javier Garzón{ddagger}, María Rodríguez-Muñoz, Almudena López-Fando, and Pilar Sánchez-Blázquez

From the Department of Neuropharmacology, Cajal Institute, Consejo Superior de Investigaciones Científicas, E-28002 Madrid, Spain

In mouse periaqueductal gray matter (PAG) membranes, the µ-opioid receptor (MOR) coprecipitated the {alpha}-subunits of the Gi/o/z/q/11 proteins, the G{beta}1/2 subunits, and the regulator of G-protein signaling RGS9-2 and its partner protein G{beta}5. RGS7 and RGS11 present in this neural structure showed no association with MOR. In vivo intracerebroventricular injection of morphine did not alter MOR immunoreactivity, but 30 min and 3 h after administration, the coprecipitation of G{alpha} subunits with MORs was reduced by up to 50%. Furthermore, the association between G{alpha} subunits and RGS9-2 proteins was increased. Twenty-four hours after receiving intracerebroventricular morphine, the G{alpha} subunits left the RGS9-2 proteins and re-associated with the MORs. However, doses of the opioid able to induce tolerance promoted the stable transfer of G{alpha} subunits to the RGS9-2 control. This was accompanied by Ser phosphorylation of RGS9-2 proteins, which increased their co-precipitation with 14-3-3 proteins. In the PAG membranes of morphine-desensitized mice, the capacity of the opioid to stimulate G-protein-related guanosine 5'-O-(3-[35S]thiotriphosphate) binding as well as low Km GTPase activity was attenuated. The in vivo knockdown of RGS9-2 expression prevented morphine from altering the association between MORs and G-proteins, and tolerance did not develop. In PAG membranes from RGS9-2 knockdown mice, morphine showed full capacity to activate G-proteins. Thus, the tolerance that develops following an adequate dose of morphine is caused by the stabilization and retention of MOR-activated G{alpha} subunits by RGS9-2 proteins. This multistep process is initiated by the morphine-induced transfer of MOR-associated G{alpha} subunits to the RGS9-2 proteins, followed by Ser phosphorylation of the latter and their binding to 14-3-3 proteins. This regulatory mechanism probably precedes the loss of MORs from the cell membrane, which has been observed with other opioid agonists.


Received for publication, June 23, 2004 , and in revised form, January 3, 2005.

* This work was supported by Ministerio de Ciencia y Tecnología Grants SAF2003-01121 and BMC2002-03228 and Comunidad Autonoma de Madrid Grant 08.8/0003/2003-1. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

{ddagger} To whom correspondence should be addressed: Neurofarmacología, Inst. Cajal, CSIC, Avd. Dr. Arce 37, E-28002 Madrid, Spain. Tel.: 34-91-585-4733; Fax: 34-91-585-4754; E-mail: jgarzon{at}cajal.csic.es.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.